Gilead Sciences, Inc. (BVL:GILDUS)
Peru · Delayed Price · Currency is PEN · Price in USD | Market Cap | 690.39B +33.7% |
| Revenue (ttm) | 104.00B +5.5% |
| Net Income | -11.06B |
| EPS | -8.93 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 18.15 |
| Dividend | 11.00 (2.09%) |
| Ex-Dividend Date | Sep 15, 2026 |
| Volume | n/a |
| Open | n/a |
| Previous Close | 147.92 |
| Day's Range | n/a |
| 52-Week Range | 110.25 - 153.07 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 29, 2026 |
About Gilead Sciences
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an inj... [Read more]
Financial Performance
In 2025, Gilead Sciences's revenue was $29.44 billion, an increase of 2.40% compared to the previous year's $28.75 billion. Earnings were $8.51 billion, an increase of 1672.92%.
Financial numbers in USD Financial StatementsNews
Gilead price target raised to $172 from $168 at BofA
BofA raised the firm’s price target on Gilead (GILD) to $172 from $168 and keeps a Buy rating on the shares after the company announced results from the phase 2…
Gilead to present new data across HIV, antiviral research at IDWeek
Gilead (GILD) Sciences taking place October 21-24 in Washington, D.C. The 28 presentations, including two oral presentations, will feature research in HIV treatment, HIV prevention and new insights in...
Gilead to Present New Data Across HIV and Emerging Antiviral Research at IDWeek 2026
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) will present new findings from its HIV and antiviral research and development programs at IDWeek 2026, taking place October 2...
Gilead's pill succeeds in mid-stage bowel disease trial
Gilead Sciences said on Monday its experimental once-daily pill reduced symptoms of a chronic bowel illness in more patients than placebo in a mid-stage trial.
Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2026 financial results and guidance will be released on Thursday, October ...
The Big 3: MRK, GILD, XOM
The significant rotation in the AI trade, particularly in neoclouds like CoreWeave (CRVW), is something Dan Deming believes opens the door to new trading opportunities. He sees Merck (MRK) leading a s...
Vir Biotechnology enters collaboration, license agreement with Gilead
Vir Biotechnology (VIR) announced a collaboration and license agreement with Gilead (GILD) to discover and engineer three novel PRO-XTEN dual-masked T-cell engager, TCE, development candidates targeti...
Gilead price target raised to $168 from $162 at BofA
BofA raised the firm’s price target on Gilead (GILD) to $168 from $162 and keeps a Buy rating on the shares after updating estimates ahead of the company’s Q3 report.
Gilead price target raised to $126 from $123 at RBC Capital
RBC Capital analyst Brian Abrahams raised the firm’s price target on Gilead (GILD) to $126 from $123 and keeps a Sector Perform rating on the shares as part of a…
Gilead price target raised to $158 from $150 at Truist
Truist raised the firm’s price target on Gilead (GILD) to $158 from $150 and keeps a Buy rating on the shares as part of a broader research note previewing Q3…
Gilead price target lowered to $163 from $165 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Gilead (GILD) to $163 from $165 and keeps an Overweight rating on the shares. The firm adjusted its models for its biopharma…
Gilead price target raised to $170 from $160 at JPMorgan
JPMorgan raised the firm’s price target on Gilead (GILD) to $170 from $160 and keeps an Overweight rating on the shares. The firm expects the company to report another strong…
Cognizant announces five-year extension of its work with Gilead Sciences
Cognizant (CTSH) announced a five-year extension of its work with Gilead Sciences (GILD). Under the agreement, Cognizant will support Gilead’s continued development of DevOps capabilities and the resp...
Nurix Therapeutics announces second research term extension with Gilead
Nurix Therapeutics (NRIX) announced that Nurix and Gilead (GILD) have agreed to extend the research term for an undisclosed oncology program within the companies’ ongoing strategic collaboration by an...
More Upside Awaits for Gilead Sciences Stock. Stay Invested.
Gilead shares are up 35% since Barron's highlighted them, but our catalysts have yet to fully play out.
Gilead put volume heavy and directionally bearish
Bearish flow noted in Gilead (GILD) with 6,354 puts trading, or 4x expected. Most active are Nov-26 140 puts and 10/9 weekly 146 puts, with total volume in those strikes…
Genetic discovery yields clues toward reversal of Alzheimer's brain damage
Today we highlight a discovery with potentially important implications for future Alzheimer's research and treatments. We also report on an experimental Gilead therapy showing great promise against a...
NTHM's Index Rebalance Puts Thematic Rotation to Work
The latest rebalance of VettaFi's Thematic Rotation Quality Momentum Screened Index (TQRMS), tracked by the NBI Thematic Rotation ETF (NTHM:TSX), reshapes the portfolio around a new set of themes. GLP...
Latin America's PAHO-Gilead HIV Prevention Deal Is a Victory for Civil Society, says AHF
MEXICO CITY--(BUSINESS WIRE)-- #Gilead--AIDS Healthcare Foundation (AHF), the world's largest HIV care provider, welcomes a new agreement between Gilead Sciences and the Pan American Health Organizati...
Gilead announces expanded scope of licensing agreements for lenacapavir
Gilead (GILD) Sciences announced that it has expanded the scope of its six royalty-free voluntary licensing agreements for lenacapavir to include investigational once-yearly lenacapavir for HIV preven...
Gilead Accelerates Global Access Planning for Investigational Once-Yearly Lenacapavir for HIV Prevention
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has expanded the scope of its six royalty-free voluntary licensing agreements for lenacapavir to incl...
Gilead announces agreement with PAHO for lenacapavir access
Gilead (GILD) Sciences announced a new agreement with the Pan American Health Organization, or PAHO, to accelerate access to twice-yearly lenacapavir for HIV prevention as pre-exposure prophylaxis acr...
Gilead, PAHO agree on HIV prevention drug access in Latin America, Caribbean
U.S. drugmaker Gilead Sciences said on Tuesday it had reached an agreement with the Pan American Health Organization to widen access to its HIV prevention drug across Latin America and the Caribbean...
Gilead and PAHO Announce Milestone Partnership to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention Across Latin America and the Caribbean
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced a new agreement with the Pan American Health Organization (PAHO) to accelerate access to twice-yearly lenacap...